<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152464</url>
  </required_header>
  <id_info>
    <org_study_id>A00309</org_study_id>
    <nct_id>NCT00152464</nct_id>
  </id_info>
  <brief_title>Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)</brief_title>
  <official_title>The Early Prevention of Asthma in Atopic Children (EPAAC™) Study. A Multi-country, Double Blind, Placebo (PLC) Controlled, Randomized, Parallel Group Trial: Evaluation of the Efficacy and Safety of Levocetirizine (LCTZ) (5 mg/ml Oral Drops -0.125 mg/kg b.w. b.i.d.) Administered for 18 Months in Preventing the Onset of Asthma in 12 to 24 Months Old Children Who Suffer From Atopic Dermatitis and Are Sensitized to Grass Pollen and / or House Dust Mite Allergens.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <brief_summary>
    <textblock>
      The Early Prevention of Asthma in Atopic Children (EPAAC™) . 24 months study to evaluate the
      efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24
      months old children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the effect of LCTZ and PLC on the time to onset of asthma after 18 months of treatment, in asthma free young atopic children sensitized to Grass Pollen (GP) and/or House Dust Mite allergens (HDM).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the symptoms and medications used for asthma; investigate consistency of treatment effect found overall on the time to onset of asthma during treatment period; Assess safety of long-term use of LCTZ in a large population of children.</measure>
  </secondary_outcome>
  <enrollment>2500</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEVOCETIRIZINE</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inclusion criteria which must be verified during screening visit (V1):

               -  Children of either sex aged between 12 and 24 months.

               -  Subjects suffering from symptoms of Atopic Dermatitis (AD) lasting cumulatively
                  for at least 2 months since birth.

               -  Modified SCORAD Index ≥ 10

               -  Subjects whose biological mother or father, or one sibling has a well-documented
                  history of atopy (AD, allergic rhinitis or asthma).

        Inclusion criteria which must be verified during randomization (V2):

          -  Results of the RAST test for GP and HDM are available and IgE level against GP ≥ 0.35
             kUA/l and / or IgE level against HDM ≥ 0.35 kUA/l.

          -  Safety laboratory results are within the normal range of the central laboratory or
             considered as not clinically significant or study disease related by the Investigator.

        Exclusion Criteria:

          -  Exclusion criteria to verify at screening visit (V1):

        Are to be excluded from the participation in the study, those children who

          -  Have height or weight below the 5th percentile.

          -  Have experienced at least one episode of wheezing when aged 6 months or over.

          -  Have suffered at age 6 months or over, from at least one nocturnal cough episode
             consisting of 3 (or more) consecutive nights resulting in sleep disturbances in a
             clinical setting where asthma is likely and other conditions have been excluded.

          -  Have chronic pulmonary diseases of any type, such as, but not limited to, cystic
             fibrosis, or any cranio-facial abnormality, e.g., cleft palate.

          -  Have a personal history of sleep apnea or who have siblings with a history of sleep
             apnea.

          -  Are treated with any immunomodulator medication such as, e.g., cyclosporin,
             cyclophosphamide or FK 506 (Tacrolimus).

          -  Have received or are receiving allergen - specific immunotherapy.

          -  Suffer from concomitant dermatological disease/condition other than atopic dermatitis,
             that might interfere with the evaluation of the clinical response for atopic
             dermatitis.

          -  Have an insufficient wash-out period for the following medications:

          -  Intranasal or systemic antihistamines: 3 days,

          -  Intranasal or systemic decongestants: 3 days,

          -  Loratadine, Desloratadine: 10 days,

          -  Chromones: 2 weeks,

          -  Oral corticosteroids: 1 month,

          -  Chronic use (i.e. cumulatively up to 2 weeks within the last 3 months) of
             inhaled/intranasal corticosteroids: 1 month,

          -  Ketotifen: 1 month,

          -  Astemizole: 6 weeks

          -  Have been treated with any antihistamine, including ketotifen, with daily intake for
             more than 2 consecutive months in the last 6 months before screening.

        Subject Exclusion criteria to verify at randomization visit (V2):

        • Intake of any prohibited medication listed above during the selection period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>UCB Pharma</affiliation>
  </overall_official>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/A00309_CSS_20070803.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <last_update_submitted>April 9, 2015</last_update_submitted>
  <last_update_submitted_qc>April 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2015</last_update_posted>
  <keyword>EPAAC , atopic Children, asthma, XYZAL, levocetirizine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levocetirizine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 10, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

